The federal picture finally moved — just not on the compound this site spends most of its time on. On August 26, 2026, the DEA published a temporary order placing three 7-OH-related synthetics — mitragynine pseudoindoxyl, MGM-15, and MGM-16 — in Schedule I. It took effect the day it printed and runs through August 26, 2028. Concentrated 7-OH itself is still not federally scheduled. We checked the Federal Register again this morning, September 8: the newest filing on 7-OH is a notice pushing the comment deadline on its threshold to Wednesday, September 10.
If those three names mean nothing to you, that's by design. All of them are made in a lab from purified kratom alkaloids. Mitragynine pseudoindoxyl is what 7-OH becomes when it's chemically rearranged; MGM-15 is a modified 7-OH; MGM-16 is a research chemical that vendors had begun listing for sale. The DEA's own filing puts their potency in animal studies at roughly 100 times mitragynine for the first, 50 times morphine for the second, and 240 times morphine for the third. They were being sold as fruit-flavored chewable tablets at two to four dollars apiece, in gas stations and smoke shops, often labeled “botanical” or “not for human consumption.”
The order reads like a coroner's report. The DEA's toxicology program found mitragynine pseudoindoxyl in at least 56 overdose cases between February 2025 and May 2026, 48 of them fatal, and MGM-15 in 17 cases over three months this spring, 16 of them fatal. A study of 51 “pseudoindoxyl” products sold online found that 71% also contained 7-OH. That last number is the one that matters for readers here: a lot of what's sold as a 7-OH tablet is actually a blend, and the blend is now a Schedule I drug in every state.
Practically, as of August 26 anyone who makes, sells, ships, or possesses these three compounds is handling a federal Schedule I substance, with no sell-through period. The DEA says it isn't after plain leaf — the order is aimed at “deliberately manufactured and concentrated opioid products, not traditional botanical kratom,” and the Justice Department says it will use enforcement discretion where only incidental trace amounts turn up in ordinary kratom. That's a reassurance for people who drink kratom tea. It is not one for anyone holding a pack of MGM-15 tablets.
So why not 7-OH? The same morning the order printed, HHS's Office of the Assistant Secretary for Health extended the public comment window on the 7-OH threshold — the 0.05%, one-milligram line that separates leaf from concentrate — from July 31 to September 10. Groups that advocate for 7-OH asked for the extra time after more than 32,000 comments came in during the first round. The scope is narrow: HHS says it wants data on where the threshold should sit, not opinions on whether 7-OH should be scheduled at all. When the window closes, the comments go to the Attorney General, and the order can issue whenever the DEA is ready.
Read that as a two-day pause with a known end date, not a reprieve. It's hard to see the order publishing while HHS is still collecting comments on the threshold it's built around; that would make the extension pointless. After Wednesday, we're back to where we've been since August 5: it can issue any weekday morning, it takes effect the day it prints, and nobody outside the agency knows which morning. The American Kratom Association's Mac Haddow has guessed “a month at the earliest.” We'd treat that as a guess.
In Palm Beach County, none of this changes what's legal on the shelf. Concentrated 7-OH and its related compounds have been Schedule I under Florida's emergency rule for more than a year, and the June 22 expansion was written to reach exactly the kind of related compounds the DEA just named. What the federal order adds is reach: an online seller shipping tablets into Florida from a state with no ban is now breaking federal law, not just ours.
If you use 7-OH or any of these tablets daily, the useful move hasn't changed and the clock on it just got shorter. Talk to a doctor or a treatment program while supply is still predictable, and be exact about what you take — brand, milligrams, times a day — because the label may not say what's really in it. 7-OH withdrawal is opioid withdrawal, and the DEA's order says the same about these three. A planned taper with medical support beats an unplanned cold-turkey week when the shelves clear.
The safety note stands: don't quit abruptly on your own to get ahead of this. Talk to a doctor, an urgent care, or a treatment program first. In crisis, call or text 988. For treatment referrals any time, day or night, SAMHSA is at 1-800-662-4357. This is education, not medical advice.